Cornercap Investment Counsel Inc. Has $263,000 Stock Holdings in Tenaya Therapeutics, Inc. (NASDAQ:TNYA)

Cornercap Investment Counsel Inc. lifted its stake in shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA) by 136.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 81,255 shares of the company’s stock after purchasing an additional 46,847 shares during the quarter. Cornercap Investment Counsel Inc.’s holdings in Tenaya Therapeutics were worth $263,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. RA Capital Management L.P. increased its stake in Tenaya Therapeutics by 10.7% during the 3rd quarter. RA Capital Management L.P. now owns 6,718,483 shares of the company’s stock valued at $17,132,000 after purchasing an additional 651,000 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in shares of Tenaya Therapeutics by 111.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,472,202 shares of the company’s stock worth $8,989,000 after acquiring an additional 2,357,950 shares during the last quarter. FMR LLC lifted its position in Tenaya Therapeutics by 32.9% in the 1st quarter. FMR LLC now owns 3,760,296 shares of the company’s stock valued at $10,717,000 after acquiring an additional 929,820 shares in the last quarter. BlackRock Inc. boosted its stake in Tenaya Therapeutics by 30.5% during the 2nd quarter. BlackRock Inc. now owns 3,636,148 shares of the company’s stock valued at $21,344,000 after purchasing an additional 850,661 shares during the last quarter. Finally, Vanguard Group Inc. increased its holdings in Tenaya Therapeutics by 8.4% during the 3rd quarter. Vanguard Group Inc. now owns 2,167,868 shares of the company’s stock worth $5,528,000 after purchasing an additional 168,489 shares in the last quarter. 90.54% of the stock is currently owned by institutional investors and hedge funds.

Tenaya Therapeutics Trading Down 3.6 %

NASDAQ TNYA opened at $4.30 on Thursday. The business’s fifty day moving average is $5.29 and its 200-day moving average is $3.57. Tenaya Therapeutics, Inc. has a one year low of $1.66 and a one year high of $8.09.

Tenaya Therapeutics (NASDAQ:TNYA) last announced its quarterly earnings data on Monday, March 18th. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.05. Equities analysts predict that Tenaya Therapeutics, Inc. will post -1.7 EPS for the current year.

Insider Transactions at Tenaya Therapeutics

In related news, CEO Faraz Ali sold 6,358 shares of the company’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $5.86, for a total value of $37,257.88. Following the transaction, the chief executive officer now owns 113,079 shares in the company, valued at $662,642.94. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, CEO Faraz Ali sold 6,358 shares of Tenaya Therapeutics stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $5.86, for a total value of $37,257.88. Following the completion of the sale, the chief executive officer now owns 113,079 shares of the company’s stock, valued at approximately $662,642.94. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, major shareholder Group Gp Lp Column III acquired 2,222,222 shares of the company’s stock in a transaction on Monday, February 12th. The shares were acquired at an average cost of $4.50 per share, for a total transaction of $9,999,999.00. Following the completion of the acquisition, the insider now owns 13,599,275 shares of the company’s stock, valued at $61,196,737.50. The disclosure for this purchase can be found here. Insiders sold a total of 20,908 shares of company stock worth $122,867 in the last quarter. Insiders own 33.83% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently issued reports on TNYA. HC Wainwright reaffirmed a “buy” rating and set a $18.00 target price on shares of Tenaya Therapeutics in a research report on Tuesday, March 19th. Chardan Capital reiterated a “buy” rating and issued a $20.00 target price on shares of Tenaya Therapeutics in a research note on Thursday, March 21st. Finally, Canaccord Genuity Group dropped their price target on shares of Tenaya Therapeutics from $19.00 to $18.00 and set a “buy” rating on the stock in a research report on Wednesday, March 20th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $15.40.

Tenaya Therapeutics Company Profile

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.